Search Results

Containing any of the words

Only of the type

"A PHASE 2/3, MULTICENTER, MULTINATIONAL,OPEN-LABEL STUDY TO EVALUATE THE EFFICACY ANDSAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUMCOFACTOR DEFICIENCY (MOCD) TYPE A" Drug Clinical Trial

Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI) Drug Clinical Trial

Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI) Drug Clinical Trial

SFDA Withdrawal a Batch for the Profinal Susp 100mg-5ml (110ml) which Produced by the manufacturer JULPHAR duo to Quality Defect Warnings

Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%) Drug Clinical Trial

The “SFDA” Inspects 124 Domestic and Foreign Pharmaceutical Manufacturers and Suspends the Registration of 11 of them in 2019. News